Truveta, a health data startup launched in 2020, announced the massive undertaking Jan. 13 along with biotech firm Illumina and the Regeneron Genetics Center, an arm of Fortune 500 company ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...